PERNIX THERAPEUTICS HOLDINGS, INC.
|
(Exact name of registrant as specified in its charter)
|
Maryland
|
001-14494
|
33-0724736
|
||
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
10 North Park Place, Suite 201
Morristown, New Jersey
|
07960
|
|
(Address of principal executive offices)
|
(Zip Code)
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
●
|
The audited statements of assets acquired as of December 31, 2014 and 2013 and statements of revenues and direct expenses of the Zohydro ER® product line for the years ended December 31, 2014 and 2013, and the notes related thereto, which is filed as Exhibit 99.2 to this Current Report on Form 8-K/A and is incorporated herein by reference.
|
●
|
The unaudited statements of assets acquired as of March 31, 2015 and 2014 and statements of revenues and direct expenses of the Zohydro ER® product line for the three months ended March 31, 2015 and 2014, and the notes related thereto, which is filed as Exhibit 99.3 to this Current Report on Form 8-K/A and are incorporated herein by reference.
|
Exhibit No.
|
Description
|
|
23.1
|
Consent of Independent Auditors.
|
|
99.1+
|
Press Release of Pernix Therapeutics Holdings, Inc. dated April 24, 2015.
|
|
99.2
|
Audited Statements of Assets Acquired as of December 31, 2014 and 2013 and Statements of Revenues and Direct Expenses of the Zohyrdo ER® product line for the years ended December 31, 2014 and 2013 and the notes related thereto.
|
|
99.3
|
Unaudited Statement of Assets Acquired as of March 31, 2015 and 2014 and Statements of Revenues and Direct Expenses of the Zohydro ER® product line for the three months ended March 31, 2015 and 2014, and the notes related thereto.
|
|
99.4
|
Unaudited pro forma condensed combined balance sheet as of March 31, 2015 and unaudited pro forma condensed combined statements of operations and comprehensive income (loss) for the year ended December 31, 2014 and for the three months ended March 31, 2015, and the notes related thereto.
|
PERNIX THERAPEUTICS HOLDINGS, INC.
|
|||
Dated: June 16, 2015
|
By:
|
/s/ Michael Golembiewski
|
|
Michael Golembiewski
|
|||
VP Finance, Corporate Controller
(Principal Accounting Officer)
|
|||
Exhibit No.
|
Description
|
|
23.1
|
Consent of Independent Auditors.
|
|
99.1+
|
Press Release of Pernix Therapeutics Holdings, Inc. dated April 24, 2015.
|
|
99.2
|
Audited Statements of Assets Acquired as of December 31, 2014 and 2013 and Statements of Revenues and Direct Expenses of the Zohyrdo ER® product line for the years ended December 31, 2014 and 2013 and the notes related thereto.
|
|
99.3
|
Unaudited Statement of Assets Acquired as of March 31, 2015 and 2014 and Statements of Revenues and Direct Expenses of the Zohydro ER® product line for the three months ended March 31, 2015 and 2014, and the notes related thereto.
|
|
99.4
|
Unaudited pro forma condensed combined balance sheet as of March 31, 2015 and unaudited pro forma condensed combined statements of operations and comprehensive income (loss) for the year ended December 31, 2014 and for the three months ended March 31, 2015, and the notes related thereto.
|